• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Spironolactone not beneficial in heart failure with preserved ejection fraction [TOPCAT trial]

byHayley Walker, MD
April 9, 2014
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Wiki

1. There was no significant difference in the primary composite outcome (death from cardiovascular causes, aborted cardiac arrest, and hospitalization for heart failure) between the spironolactone and placebo groups. 

2. Post hoc analyses showed that spironolactone benefited patients in the Americas but not Russia or Georgia, where event rates were lower. 

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Mineralocorticoid-receptor antagonists such as spironolactone have been shown to reduce mortality and hospitalizations in patients with heart failure with reduced ejection fraction. The multicenter, international Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial was designed to test whether spironolactone also improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF). Patients were enrolled if they had a history of hospitalization with management of heart failure or if they met brain natriuretic peptide (BNP) criteria. The study found that spironolactone did not significantly reduce the incidence of the primary outcome, which was a composite of death from cardiovascular causes, aborted cardiac arrest, and hospitalization for heart failure. When the components of the primary outcome were considered individually, only hospitalization for heart failure was significantly reduced in the spironolactone group compared to the placebo group.

Because the primary endpoint was not met, all other analyses must be interpreted with caution. However, there is currently no medical therapy that has been shown to improve outcomes in HFpEF; it is therefore especially important to consider which subgroups of patients with HFpEF might benefit from spironolactone. Post hoc analyses revealed that patients in Russia and Georgia did not benefit from spironolactone; these patients had lower event rates and were more likely to be enrolled according to the hospitalization criterion than the BNP criterion. It is also possible that some enrolled participants did not have HFpEF, which causes non-specific symptoms and is difficult to diagnose. In contrast, patients enrolled in the Americas benefited from spironolactone and had higher event rates. Further research is needed to clarify which, if any, subgroups of patients with HFpEF could benefit from spironolactone.

Click to read the study, published today in NEJM

RELATED REPORTS

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

Clinical decision-making strategy improves acute heart failure outcomes

Ferric derisomaltose may reduce heart failure-related hospitalizations

Click to read an accompanying editorial in NEJM

Relevant Reading: The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

In-Depth [randomized controlled trial]: This multicenter, international study randomized 3,445 patients with HFpEF to receive either spironolactone or placebo. In order to be eligible, patients had to either have a history of hospitalization within the previous 12 months for management of heart failure (hospitalization stratum) or have an elevated BNP level within 60 days before randomization (BNP stratum). Randomization was stratified according to whether the patient met the hospitalization or BNP criterion. The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest and hospitalization for management of heart failure.

After a mean follow-up period of 3.3 years, the incidence rate of the primary outcome was 5.9 events per person-years in the spironolactone group and 6.6 events per 100 person-years in the placebo group (HR 0.89; 95% CI, 0.77 to 1.04). When the components of the primary outcome were considered individually, only hospitalization for heart failure was significantly more common in the placebo group (12% of spironolactone vs. 14.2% of placebo group; HR 0.83; 95% CI, 0.69 to 0.99). Exploratory post hoc analyses demonstrated that patients from Russia and Georgia did not benefit from spironolactone; event rates in this population were low and the majority of patients were enrolled in the hospitalization stratum. In contrast, patients in the Americas did benefit significantly from spironolactone; these participants were more evenly distributed between the two strata and had higher event rates.

More from this author: Mutations in PKA catalytic subunit associated with Cushing’s syndrome, Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial], Solanezumab does not improve cognition or functioning in Alzheimer’s disease [EXPEDITION trials], Low brown fat may explain increased susceptibility to type 2 diabetes in south Asians, Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: heart failurespironolactone
Previous Post

Financial incentives improve Hep B vaccination rate among injection drug users

Next Post

Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

January 24, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Next Post
Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

RAS mutation linked with survival in metastatic colorectal cancer

Colorectal cancer resection associated with more complications in elderly

HLA-DRB1*07:01 confirmed as risk factor for lapatinib-induced liver damage

Cetuximab and neoadjuvant chemotherapy may decrease survival in liver metastasis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options